Retinopathy of Prematurity Clinical Trial
Official title:
Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids
The primary objectives of this study are to compare the serum and skin concentrations of
beta-carotene, lutein, and lycopene in preterm infants fed preterm formulas with mixed
carotenoids to serum concentrations in preterm infants fed preterm formulas with no added
carotenoids and to human milk fed infants.
The secondary objective of this study is to evaluate the effects of dietary carotenoids on
the developing eye. Stages and zones of retinopathy of prematurity (ROP), retinal function,
and retinal characteristics will also be examined.
Infants that are born prior to 37 weeks gestation often face complications resulting from
their prematurity. Preterm infants are susceptible to morbidities that are not common in
healthy term infants. Underdeveloped organs such as the lungs, eye, intestine, and brain can
reveal conditions unique to prematurity: chronic lung disease, bronchopulmonary dysplasia
(BPD), retinopathy of prematurity (ROP), necrotizing enterocolitis, intraventricular
hemorrhage (IVH), etc. Infants in the Newborn Intensive Care Unit (NICU) have increased
inflammation and oxidative stress in association with common diseases of prematurity and as
well as the treatments used to combat their illnesses (Gitto et al 2004; Ochoa et al 2003;
Saugstad 2003).
According to the National Eye Institute (U.S. National Institutes of Health), retinopathy of
prematurity affects approximately 50% of preterm infants that are born weighing 1250 g or
less. While 90% of infants with retinopathy of prematurity (ROP) experience the milder form
of the disease, which requires little or no medical treatment, severe ROP can lead to
serious visual impairments or even blindness. This condition is of particular interest since
Hylander et al. (Hylander et al 2001) have reported that human milk feeding of preterm
infants (<1500 g birth weight) has been associated with a lower incidence of ROP and this
association was proposed to be driven by the antioxidant content of human milk. Human milk
provides a variety of antioxidants to the breastfed infant, including the carotenoids
lutein, zeaxanthin, lycopene, and beta-carotene. As discussed earlier, lutein and zeaxanthin
are concentrated to the eye and are thought to provide protection against both light-induced
and metabolic oxidative damage.
The retina and retinal vasculature are the last eye structures to develop in the human
fetus/neonate. Eyes of children with a history of ROP are reported to have retinal thinning
with diffuse hypopigmentation, mild linearization, or mild tortuosity of the major vessel
branch, mottled pigmentation of the macula, and other peripheral retinal anomalies
(Minicucci et al 1999). The lack of pigmentation in the retinal structure might be explained
by the deficit of lutein acquired by the fetus (by placental transfer during late gestation)
or by the neonate through the diet (by preterm infant formulas devoid of these carotenoids).
Preterm infants are at a nutritional disadvantage at birth as they have been deprived of the
period of maximal transfer of nutrients during the last few weeks of pregnancy. Blood levels
of beta-carotene have been associated with gestational age (Ostrea et al 1986) and cord
blood levels of beta-carotene (Herrera et al 2004; Kiely et al 1999; Yeum et al 1998),
lutein (Kiely et al 1999), and lycopene (Herrera et al 2004; Kiely et al 1999) were reported
to be significantly lower than maternal levels. Stores of fat-soluble antioxidant vitamins
also could be compromised due to the minimal fat deposition in the preterm infant.
It is therefore reasonable to suggest that providing preterm infants with a milk-based
ready-to-feed (RTF) preterm infant formula with DHA and ARA supplemented with carotenoids,
which are found in human milk, would result in serum carotenoid levels more like the
breastfed infant. Further, increased dietary carotenoid intake by preterm infants might
decrease the prevalence of morbidities that are associated with prematurity, such as ROP,
bronchopulmonary dysplasia (BPD), and intraventricular hemorrhage (IVH).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043077 -
Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening
|
Phase 4 | |
Completed |
NCT04838665 -
Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study
|
Phase 4 | |
Completed |
NCT04408807 -
Stress Induced by Screening for Retinopathy of Prematurity - Should Speculum and Indentation Rather be Avoided
|
N/A | |
Recruiting |
NCT03083431 -
Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity
|
Phase 2 | |
Enrolling by invitation |
NCT04985448 -
Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data
|
||
Recruiting |
NCT02090322 -
Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1
|
N/A | |
Unknown status |
NCT00254176 -
Cysteine Supplementation in Critically Ill Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT06452524 -
Prematurity and Ophthalmological Changes
|
||
Completed |
NCT04101721 -
Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
|
Phase 3 | |
Enrolling by invitation |
NCT02050971 -
Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates
|
Phase 1 | |
Terminated |
NCT01335113 -
A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity
|
||
Active, not recruiting |
NCT00027222 -
The Early Treatment for Retinopathy of Prematurity Study (ETROP)
|
Phase 2/Phase 3 | |
Recruiting |
NCT06109285 -
Validation of i-ROP DL to Detect More Than Mild ROP
|
N/A | |
Completed |
NCT02014454 -
Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature
|
Phase 2 | |
Completed |
NCT01861470 -
REDEXAM - Reducing Painful Eye Examinations in Preterm Infants
|
N/A | |
Terminated |
NCT00634972 -
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
|
Phase 4 | |
Completed |
NCT05701124 -
Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity
|
Phase 3 | |
Completed |
NCT04092127 -
Pain of Premature Babies and RetCam (DOLICAM)
|
||
Completed |
NCT04621136 -
PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity
|
Phase 1/Phase 2 | |
Completed |
NCT04883931 -
Mother Milk as a Eye Drop & Premature Retinopathy
|
N/A |